DEVELOPMENT JOURNEY TO REPLACE NEURONS LOST TO ALZHEIMER’S DISEASE WITH NEURAL PRECURSOR CELLS DERIVED FROM SKIN CELLS
With
Professor Michael Valenzuela,
Founder and Chief Scientific Officer,
Skin2Neuron
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | June 2026
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
He studied psychology at the University of New South Wales (UNSW) before completing a PhD on Cognitive Reserve. This work was recognised by one of the nation’s top awards, the Australian Museum Eureka Prize for Medical Research.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
Between 2019-2021 he was employed as a senior advisor to the WHO in one of its flagship Decade of Healthy Ageing initiatives. He also joined the Centre for Healthy Brain Ageing at UNSW as Visiting Professor and played a leading role in the design and successful completion of the Maintain Your Brain – the world’s largest dementia prevention trial that found it is possible to delay cognitive decline in older at-risk people by about 1-year.
Professor Valenzuela is a frequent media commentator and author of the popular science book Maintain Your Brain.
Source: Supplied
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
-
The focus on reducing instances of birth-trauma through trauma-informed care
Leading into Birth Trauma Week 2026, in an interview with Australian Health Journal, Dr Nisha Khot, President of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), highlighted the growing focus on reducing birth trauma through trauma-informed, multidisciplinary care.
